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The Potential of Immune Biomarkers to Advance Personalized Medicine Approaches for 
Schizophrenia 
Abstract 
Molecular profiling studies have helped increase the understanding of the immune processes 
thought to be involved in the etiology and pathophysiology of psychiatric disorders such as 
schizophrenia. Current therapeutic interventions with first and second generation antipsychotics are 
suboptimal. Poor response rates and debilitating side effects often lead to poor treatment 
compliance. This highlights the pressing need to identify more effective treatments as well as 
objective biomarker based tests which can help predict treatment response and identify diagnostic 
subpopulations. Such tests could enable early detection of patients who will benefit from particular 
therapeutic interventions.  In this review, we discuss studies relating to dysfunctions of the immune 
system in schizophrenia patients and the effects of antipsychotic medication on the molecular 
components of these systems. Immune system dysfunction may in part be related to genetic risk 
factors for schizophrenia, but there is substantial evidence that a wide range of environmental 
factors ranging from exposure to infectious agents such as influenza and Toxoplasma gondii to HPA 
axis dysfunction play an important role in the etiopathogenesis of schizophrenia. Ongoing research 
efforts, testing therapeutic efficacy of anti-inflammatory agents used as add-on medications are also 
discussed. From a therapeutic perspective these represent the initial steps towards novel treatment 
approaches and more effective patient care in the field of mental health. 
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1: Introduction 
Schizophrenia is a major psychiatric disorder which affects up to 1% of the global population and has 
been listed among the world’s top ten causes of disease-related disability (Tandon et al., 2008). It 
has an annual incidence rate of around 15 in every 100,000 people and the lifetime risk of 
developing the disease is approximately 0.7%.  
The development of effective treatments for schizophrenia patients has been hampered by a lack of 
significant innovations over the past 60 years since first-generation (typical) antipsychotics were 
introduced in the 1950s. First and second-generation (atypical) antipsychotics can be associated with 
poor response rates and prominent side effects.   
As a result there is a great need to improve our understanding of the complex and diverse 
underlying pathophysiological mechanisms associated with the schizophrenia disease process at the 
molecular level. This improvement will enable treatment intervention at the earliest possible stage 
and increase our understanding of the mechanisms of action of antipsychotics.  
Subgroups of schizophrenia patients may exist as some respond well to certain therapeutic 
compounds while others continue to experience severe and chronic symptoms (Tomasik et al., 
2014). This distinction highlights a strong clinical need for robust biomarkers of treatment response 
which can enable the detection of patient subgroups and inform individual treatment strategies at 
an early stage. 
This review will discuss the extent to which previous studies have increased our understanding of 
how “biomarkers” for schizophrenia are modulated by antipsychotic medication. In particular we will 
consider biomarkers involved in immune function which have been implicated in the disease process 
of schizophrenia. The review will also consider the potential use of combination therapies which can 
be used in early intervention, i.e. combining existing antipsychotics with adjunctive treatments such 
as anti-inflammatory agents. Initial studies have already provided promising results of increased 
efficacy in some patients. In the future it may be possible to apply these treatments to patient sub-
groups who display specific molecular traits.     
2: Immune System and Inflammatory Biomarkers 
2.1. The immune system as a target for pharmacological interventions 
The immune system has been suggested as a novel therapeutic target for schizophrenia, due to 
evidence from neurobiological, genetic and environmental studies suggesting that alterations in 
immune function may be associated with the disease pathogenesis in at least a subgroup of patients 
(Potvin et al., 2008 and Chan et al., 2011). Schizophrenia patients and their relatives are often found 
to have a higher or lower than expected prevalence of auto-immune disorders such as autoimmune 
encephalitis, rheumatoid arthritis and celiac disease (Benros et al., 2011).  
Genetics has provided considerable evidence that immune system dysfunction plays a key role in the 
pathophysiology of schizophrenia (Smyth and Lawrie, 2013). A 2013 study identified 144 genes 
relating to inflammation and immune response in the hippocampus of schizophrenia patients, which 
were differentially expressed compared to controls (Hwang et al., 2013). This study follows on from 
previous work identifying various gene loci on chromosome 6 as having the strongest association 
with the disease (Schizophrenia Psychiatric GWAS Consortium, 2011), a notable finding as this region 
includes a number of genes involved in immune function. Studies have also pointed to the potential 
harmful role of activated inflammatory processes in schizophrenia on the central nervous system 
(CNS) (Drexhage et al., 2011). These processes can result from a variety of factors including disease 
stage, infectious disease (as discussed further in section 3), the side effects of antipsychotic 
medication and other environmental risk factors. Inflammation represents a protective mechanism 
and this cellular response is controlled in both the periphery and CNS by immunomodulatory 
mechanisms through the up- or down-regulation of pro or anti-inflammatory cytokines/mediators 
and their receptors (Smyth and Lawrie, 2013).  
Cytokines are soluble proteins secreted by a variety of different cells. Many cytokines are capable of 
passing the blood-brain barrier (BBB) and inducing changes in behaviour and cognition by altering 
brain function, for example through the hypothalamic–pituitary–adrenal (HPA) axis (Watanabe et al., 
2010). This suggests that the CNS and the immune system are interconnected rather than being 
isolated as previously thought (Simard and Rivest, 2005). This interaction plays a key role in 
regulating dopaminergic and GABAergic neuronal differentiation as well as neuronal migration and 
synaptic maturation (Namba et al., 2006). Studies have suggested that processes leading to immune 
alterations in the CNS may originate in the periphery (Kirch et al., 1992). Altered levels of cytokines 
and other inflammatory markers have been found in schizophrenia patients in the blood and 
cerebrospinal fluid (Potvin et al., 2008, and Miller et al., 2011). These molecules can then cross the 
BBB and induce a variety of harmful consequences such as neuronal inflammation, damage and 
degeneration which have been implicated in the disease (Raison and Miller, 2011).  
2.2. Inflammatory markers and antipsychotic medication 
Cytokines are involved in the pathogenesis of schizophrenia and also the response to antipsychotic 
medication. In one meta analysis of 33 studies which examined peripheral immune alterations in 
schizophrenia (Miller et al., 2011), numerous biomarkers were reported as being elevated in first 
episode and relapsed patients, including plasma concentrations of cytokines Interleukin-1 beta (IL-
1β), Interleukin-6 (IL-6) and Transforming growth factor beta (TGF-β). In particular, IL-6 levels were 
increased with an effect size of 1.4 in first episode patients. All three of these molecules were found 
to be normalized with treatment, suggesting they are state biomarkers. However Interleukin-12 (IL-
12), interferon gamma (IFN-γ), Tumor necrosis factor alpha (TNF-α) and soluble interleukin-2 
receptor (sIL-2R) were all increased in schizophrenia patients but were not altered by treatment, 
identifying them as possible trait biomarkers.  
A number of additional candidate biomarkers have been reported to change in response to 
antipsychotic treatment, including S100B, prolactin, interleukin-2 (IL-2), insulin, leptin, interleukin-1 
receptor antagonist (IL1-RA), interleukin-8 (IL-8), interleukin-2 receptor antagonist (IL-2RA) (Chan et 
al., 2011) and IL-6 which has been repeatedly reported to be increased in schizophrenia patients. 
These findings are in line with a recent 2008 meta analysis (Potkin et al., 2008) analyzing 62 studies 
of peripheral immune alterations in patients compared to controls. As this cytokine is predominantly 
produced by cells of the innate immune system, increased levels of IL-6 point towards an abnormal 
innate immune response in these patients. The study also showed that IL-6 levels decreased after 
treatment with antipsychotics. However, it remains unclear whether these changes are primarily a 
result of medication or a change in the state of the disease. IL-6 levels have been shown to differ, 
depending on whether patients are in the acute state of illness or in remission, as evidenced by 
correlation with psychopathology scores (Pae et al., 2006). IL-6 upregulation is also only seen in 
some studies but not others (Maes et al., 2000).       
Antipsychotics have been found to have differential effects on a variety of other pro-inflammatory 
cytokines. sIL-2R is a marker of immune activation, inhibiting IL-2 activity by preventing its binding to 
membrane-anchored receptors. Its levels are found to be increased above normal levels in 
schizophrenia patients (Potkin et al., 2008). However while studies have shown that sIL-2R and IL-12 
increase further with antipsychotic treatment (Potkin et al., 2008 and Miller et al., 2011), the levels 
of other pro-inflammatory proteins IL-1β and IFN-γ were found to decrease (Miller et al., 2011). This 
highlights the complexity of the relationship between antipsychotics and inflammation. The fact that 
the levels of some molecules indicate an excessive inflammatory state in the periphery may be due 
to the propensity of atypical antipsychotics to increase certain inflammatory processes, leading to 
side effects such as metabolic syndrome (Buchholz et al., 2008). Risperidone was found to have a 
particularly significant effect on increasing levels of IL-12 (Tourjman et al., 2013).      
The peripheral levels of C Reactive Protein (CRP), a protein mainly generated in the liver, are also a 
good indicator of chronic inflammation with increased levels associated with infection and 
inflammatory conditions (Lowe, 2005). There have been limited studies examining this molecule in 
schizophrenia but recent data have shown that it is increased in around 30% of patients (Dickerson 
et al., 2013 and Miller et al., 2014). A 2010 study of 111 patients examined the effects of haloperidol, 
olanzapine and risperidone on CRP levels after three months and twelve months of treatment, 
respectively (Diaz et al., 2010). Haloperidol led to an increase in the levels of CRP after three months 
but there were no significant differences between baseline and twelve month levels for any of the 
treatments. This suggests the development of tolerance to the effects of antipsychotics on CRP 
levels but the results may be skewed by the fact that a number of patients had dropped out by the 
one year time point.               
The levels of anti-inflammatory molecules, such as the cytokines IL1-RA and interleukin-10 (IL-10), 
have been found to increase in response to treatment (Potkin et al., 2008). Genetic studies have 
indicated that IL1-RA and IL-10 may play a causal role in the development of the disease through 
inhibiting normal cytokine action, resulting in altered brain and behavioural function (Dantzer, 
2004). A recent study which looked at multiplex immunoassay analyses of serum cytokines in 180 
first-onset schizophrenia patients before and after treatment with risperidone and olanzapine, found 
that the levels of both IL-10 and IL1-RA were significantly lower after six weeks of medication (De 
Witte et al., 2014). The decrease in the concentration of these anti-inflammatory cytokines is in line 
with the hypothesis that antipsychotics induce an inflammatory response which can lead to certain 
metabolic side-effects. Interestingly the decrease in IL-10 levels was also significantly correlated with 
an improvement in negative symptoms including cognitive functioning. This suggests that IL-10 may 
play an important role in the therapeutic mechanisms of these two atypical antipsychotic drugs.  
 
 
 
2.3. Potential confounding effects of psychological stress and other factors 
The clinical implications of the findings relating to pro-inflammatory molecules such as IL-6 suggest 
that a more individualized treatment approach may be appropriate for patients who display 
evidence of immune activation. For example, add-on anti-inflammatory agents could be used in 
conjunction with existing antipsychotics to target these molecules and their pathways (Keller et al., 
2013). This approach is discussed in further detail in Section 4.  
So far, a number of meta-analyses have been conducted to examine changes in inflammatory 
markers such as IL-6. However, many of these studies did not take into account methodological 
differences in storage, sample handling and methods of assessment, all of which can influence 
circulating cytokine levels. Consequently, further studies investigating cytokine responses in disease 
should account for the effects of various confounding factors. A few studies have examined some of 
the variables which may have a confounding effect on peripheral cytokine levels (Tappia et al., 
1995). For instance, a 2013 meta analysis on the effects of antipsychotics on cytokines across 23 
studies (Tourjman et al., 2013), found that age, gender and duration of illness had no effect on the 
results. However, other potential confounding factors such BMI, smoking and ethnicity were not 
considered. 
A final limitation is the possibility that more complex mechanisms such as a reduction in 
psychological stress after treatment may result in the apparent reductions seen in the levels of some 
cytokines. Evidence for the influence of stress on cytokine levels has been provided by several 
studies. For instance, increased psychological stress in healthy individuals was found to induce 
inflammatory response resulting in increased production of pro-inflammatory cytokines such as TNF-
α, IL-6, IL-1RA, IFN-γ and IL-10 (Maes et al., 1998), and similar results have been obtained for other 
psychiatric disorders such as depression (Potkin et al., 2008). It has been hypothesized that this 
happens via pathways involving defective glucocorticoid-mediated feedback inhibition and 
exaggerated sympathetic nervous system-mediated activation of immune responses (Potkin et al., 
2008). 
3. Infectious Agents 
3.1. Evidence linking infectious agents to schizophrenia 
Exposure to pathogenic microbes, either during the prenatal period or childhood, has been 
suggested as being a contributing factor to the etiology of schizophrenia by causing disruptions in 
brain development (Murray and Lewis, 1987). Studies investigating the role of specific infectious 
agents in schizophrenia have suggested that the risk is mainly posed by viruses and parasites with a 
tendency to invade the central nervous system (CNS).         
Over the past decade studies applying bioassays to measure anti-microbial antibodies in archived 
maternal serum samples have yielded some notable results. They suggest that infections posing a 
particular risk factor for schizophrenia include influenza A virus (Brown et al., 2004), polio virus 
(Suvisaari et al., 1999), rubella virus (Brown et al., 2000) and genital reproductive infections (Babulas 
et al., 2006), although the evidence surrounding herpes simplex virus type 2 is contradictory (Buka et 
al., 2008 and Brown et al., 2006). Influenza A virus has been suggested to increase the risk of 
developing schizophrenia by sevenfold when mothers are exposed to the virus during the first 
trimester of pregnancy (Brown et al., 2004).  
Considerable research has been undertaken on the parasite Toxoplasma (T.) gondii and its potential 
contribution to the etiopathogenesis of schizophrenia (Mortensen et al., 2007 and Brown et al., 
2005). Thirty eight studies have shown positive correlations between T. gondii antibody titers and 
schizophrenia, as of 2013 (Webster et al., 2013). Associations have been found between maternal 
and neonatal exposure to T.gondii and an increased risk to developing schizophrenia (Mortensen et 
al., 2007).  T.gondii is of particular interest as links have also been observed between exposure in 
adulthood and schizophrenia in studies of the US military (Niebuhr et al., 2008) and ultra-high risk 
(UHR) individuals (Amminger et al., 2007).   
A potential link has also been proposed between bacterial and viral meningitis in childhood and the 
onset of schizophrenia some years later (Leask et al., 2002).  
However while associations have been made between schizophrenia and infections years to decades 
before diagnosis, investigations into how infectious agents contribute to the pathomechanisms of 
the disorder, after a lengthy latency period, are still ongoing.  
3.2. Evidence for biomarker changes associated with exposure to infectious agents         
One theory suggests infectious agents increase the risk of schizophrenia by altering the levels of 
cytokines and other immune mediators. These molecules play a critical role in how the immune 
system deals with infection, as well as being involved in the development and functioning of the CNS 
in early life.  Some are pro-inflammatory, aiding the body deal with foreign pathogens and some are 
anti-inflammatory mediating the immune response and terminating it when no longer necessary 
(Parham, 2005 and Richard and Brahm, 2012).  
An association has been found between increased levels of pro-inflammatory cytokines in maternal 
serum, as result of exposure to infection, and psychotic illness in the offspring (Brown et al., 2004). 
For instance maternally generated cytokines have been found to cross the placenta (Li et al., 1995) 
and partially penetrate the BBB of the developing fetus and bind to glial cells and neural receptors in 
the brain (Banks et al., 1994). Additionally, elevated levels of these molecules have also been shown 
to increase susceptibility to brain damage (Dammann and Leviton, 1997) through various 
mechanisms. One hypothesis is that this occurs through the disrupted maturation of 
oligodendrocytes, resulting in white matter abnormalities which have been seen in post-mortem 
brains and in imaging studies of schizophrenia patients (Davis et al., 2003). Cytokine activity can also 
induce other biological processes including increases in oxidative stress and activation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Turnbull and Rivier, 1995).  
Clinical studies have reported increases in the levels of several cytokines in the response to infection, 
notably IL-8 and TNF- α (Brown and Derkits, 2010). These molecules may be involved in cytotoxicity 
as well as mediating dopaminergic and glutamatergic pathways which are implicated in the 
pathophysiology of schizophrenia (Girgis et al., 2014).      
Findings from animal models also suggest that IL-6 may play a key role in the development of 
schizophrenia-related phenotypes which occur as a result of maternal immune activation (MIA) 
(Smith et al., 2007). MIA was induced in pregnant rats by injecting a bacterial cell wall endotoxin 
called lipopolysaccharide (LPS) (Romero et al., 2007) and polyinosinic:polycytidylic acid (poly I:C). 
The latter imitates a viral infection by activating inflammatory signalling pathways through Toll-like 
receptor 3 via a nuclear factor κB-dependent mechanism (Smith et al., 2007) and stimulating 
cytokines such as IL-1, IL-6 and TNF-α (Gilmore et al., 2005). In both experiments IL-6 levels were 
increased, which has been linked to cognitive deficits such as spatial memory and learning 
abnormalities in rodent models.      
The potential pathophysiological consequences of infection in later life can be investigated through 
biomarkers related to infectious agents, some of which were reported to be correlated with 
functional deficits in schizophrenia. The levels of T.gondii immunoglobin G (IgG) antibodies were 
found to be positively correlated with psychotic symptoms in ultra-high risk individuals (Amminger 
et al., 2007). A recent study which looked at molecular changes in the cerebrospinal fluid (CSF) in 
schizophrenia patients saw that T.gondii antibody levels were correlated with a disease associated 
reduction in TGF-α, IL-6R and ACE (Hayes et al., 2014). Furthermore, antibodies to herpes simplex 
virus type 1 (HSV-1) have been obtained (Yolken et al., 2011). HSV-1 has been linked to impaired 
cognitive functioning (Prasad et al., 2012). A further study found that elevated serum levels of C-
reactive protein (CRP) along with exposure to HSV-1, is linked to the severity of cognitive impairment 
in schizophrenia (Dickerson et al., 2012).     
3.3. Anti-inflammatory/anti-microbial efficacy of antipsychotic medication 
The impaired cytokine signalling resulting from prenatal or childhood infection is believed to lead to 
abnormal brain development which ultimately may precipitate the onset of psychiatric symptoms 
post-adolescence. For such individuals, neonatal anti-inflammatory treatment may prove beneficial. 
As discussed in Section 2, conventional second generation antipsychotics are not always successful 
at normalizing pro-inflammatory cytokines, illustrating the importance of evaluating the anti-
inflammatory effectiveness of antipsychotics. Various rodent studies have found haloperidol and 
other medications to be useful in reducing cytokine levels following bacterial/viral exposure. A 
maternal immune activation (MIA) model applied to rats found that treatment with haloperidol was 
effective in reducing IL-6 and TNF- α serum levels (Romero et al., 2007). By applying a similar MIA rat 
model, another study (Basta-Kaim et al., 2012) showed that chronic administration of either 
chlorpromazine or the second generation antipsychotic clozapine reduced the Prepulse Inhibition 
(PPI) deficit, a behavioural correlate for schizophrenia. Both antipsychotics also modulated enhanced 
levels of TNF-α as well as those of the cytokines IL-1β and IL-2.    
Further research may lead to the discovery of new classes of antipsychotics which can be used in 
patients where the disease pathophysiology may be linked to prenatal or perinatal infection. For 
example, neonatal rodent models of schizophrenia have uncovered some potential novel 
antipsychotic treatments. Behavioural deficits were induced in rat pups through subchronic doses of 
epidermal growth factor (EGF) and Emodin, a broad tyrosine kinase inhibitor, was then found to 
eliminate PPI deficits after subchronic, oral administration (Mizuno et al., 2008). Similar results were 
achieved using a quinazoline derivative and ErbB1 inhibitor in another rodent model of the disease. 
This is a notable finding as abnormal ErbB1 signalling is thought to be a contributing factor to 
dopaminergic dysregulation in schizophrenia (Nawa and Mizuno, 2006).      
For patients believed to have been exposed to T.gondii, there is evidence that certain treatments 
may prove effective. The high levels of IgG antibodies against the parasite measured in both 
cerebrospinal fluid (CSF) and serum of drug naive schizophrenia patients, were found to be lower in 
recent-onset patients who had been receiving antipsychotic treatment (Leweke et al., 2004).     
More detailed investigations into the types of antipsychotics which work well against T.gondii, 
conducted in vitro, found that two first-generation antipsychotics – fluphenazine and zuclopenthixol 
- have high anti-toxoplasma activity and three other first-generation medications – cyamemazine, 
levopromazine and loxapine – which are often prescribed to treat acute psychotic agitation, have 
intermediate anti-toxoplasma activity (Fond et al., 2014).  Further research is needed to investigate 
the underlying molecular mechanisms behind their apparent effectiveness. This will also be required 
to verify whether these treatments could become either first-line antipsychotic medications for 
schizophrenia patients infected by T.gondii, or for use as add-on drugs to atypical antipsychotics.  
4. Antipsychotics and Anti-Inflammatory Medication for Schizophrenia 
4.1. The potential benefits of add-on anti-inflammatory medication 
Anti-inflammatory agents may provide an effective means of lowering the proinflammatory status of 
some schizophrenia patients towards levels seen in healthy controls. Studies have shown that some 
antipsychotics have anti-inflammatory activity, but the immunomodulatory activities are generally 
very limited with the exception of clozapine (Leucht et al., 2013). Recent evidence suggests that the 
efficacy of antipsychotics could be augmented if patients were given additional anti-inflammatory 
medication in conjunction with standard antipsychotic treatment (Sommer et al., 2012).  As 
heightened proinflammatory status can affect cognition by altering glutamatergic and dopaminergic 
pathways (Muller and Schwarz, 2006 and Muller and Dursun, 2011), restoring the balance between 
proinflammatory and anti-inflammatory regulators may improve cognitive symptoms.  
To date, several anti-inflammatory medications have been examined as potential add-on treatments 
to antipsychotics. These include aspirin, celecoxib, cytostatics, davunetide, estrogens, fatty acids, 
leptin, tetracyclines, melatonin, minocycline, monoclonal antibodies, N-acetyl cysteine (NAC), 
corticosteroids and drugs used in transplantation patients such as tacrolimus, cyclosporine and 
everolimus (Sommer et al., 2014).    
4.2. Evidence from clinical trials 
The results of clinical trials conducted so far have provided evidence that aspirin add-on to 
antipsychotic treatment reduces positive symptoms of schizophrenia (Laan et al., 2010), especially in 
patients in whom the disease duration has been relatively short. Aspirin is an non-steroidal anti-
inflammatory drug (NSAID) which inhibits the COX-1 enzyme and reduces inflammatory processes by 
altering the activity of COX-2, thus reducing the production of thromboxanes and prostaglandins 
(Vane et al., 1998). A randomized, double-blind, placebo-controlled study of 70 patients in the 
Netherlands showed an improvement in positive and total PANSS scores after three months of daily 
1000mg doses, but little change in cognitive function (Laan et al., 2010). However, the study did not 
examine the efficacy of aspirin over a longer time period.  
Estrogens may also be a promising supplementary treatment for female patients (Kulkarni et al., 
2008), although their effectiveness was greatly diminished when treating male schizophrenia 
patients (Kulkarni et al., 2011). They are thought to have mild anti-inflammatory activity mediated 
through various mechanisms of action including reducing levels of TNF- α, Nitric Oxide and oxidative 
stress as well as influencing dopaminergic signalling (Liu et al., 2005).      
The protein n-acetyl cycteine (NAC) has become of interest as a potential add-on treatment to 
antipsychotics as a result of the theory that antioxidant agents could be used to target the negative 
symptoms of schizophrenia.  There is accumulating evidence for abnormalities in pathways involved 
with oxidative stress in the pathophysiology of schizophrenia (Wood et al., 2009). Compared to 
healthy controls, schizophrenia patients have been shown to have decreased levels of glutathione, 
superoxide dismutase (SOD), lower plasma nitrite concentrations and reduced red blood cell 
catalase levels in first-episode patients (Flatow et al., 2013). NAC is believed to be able to cross the 
BBB (Farr et al., 2003) and reach glial cells, initiating a cellular process which results in increased 
glutathione levels (Arakawa M and Ito, 2007). Glutathione is an antioxidant which decreases cellular 
damage by scavenging reactive oxygen species (Müller and Dursun, 2011). NAC also has been shown 
to have direct free radical scavenging properties (Laan et al., 2009). In addition to its corrective 
effect on the oxidative balance, NAC possesses anti-inflammatory properties. It acts as a strong 
inhibitor on cytokines such as TNF- α, IL-6 and IL-1 β which are the main mediators of 
proinflammatory status (Palacio et al., 2011). Furthermore, it is thought to exert beneficial 
regulatory effects on glutaminergic and dopaminergic pathways, neurotransmission pathways which 
are known to be altered in schizophrenia (Oja et al., 2000).  
There have been a couple of studies (Berk et al., 2008 and Wood et al., 2009) which have attempted 
to assess the efficacy of NAC as an add-on medication to treat the negative symptoms of 
schizophrenia in chronic patients, by evaluating changes in PANSS scores. The initial study (Berk et 
al., 2008) found that 2g/day of NAC in addition to various atypical antipsychotics over a 24 week 
period, resulted in significant improvements on the negative PANSS subscale as well as on the 
general and total subscales. The second study (Wood et al., 2009) took place over just eight weeks 
with a total of 42 patients. A smaller improvement in negative PANSS scores was reported. However 
this study only looked at patients who were in an active phase of their illness (patients with a score 
of 20 or more on the negative PANSS subscale were selected) which may explain the differences 
between the two studies.        
Minocycline, davunetide, EPA and DHA fatty acids have also been evaluated in clinical trials but with 
relatively little success in augmenting the efficacy of antipsychotics. Celecoxib is a molecule which is 
able to cross the BBB (Davies et al., 2000) and blocks COX-2-mediated vascular permeability, 
preventing the extravasation of various pro-inflammatory molecules which mediate the 
inflammatory response (Simon, 1999). However the studies involving celecoxib have yielded mixed 
results, possibly due to the short duration of the trials (Muller et al., 2002, Rappard and Muller, 
2004). Interestingly, celecoxib did show a strong positive effect when it was given solely to first 
episode psychosis (FEP) patients (Muller et al., 2005) so it may be of clinical use for recent-onset 
patients.          
There is evidence that the level of the response to medication may also be strongly related to the 
initial inflammatory status. One study found that aspirin treatment yielded the greatest benefits in 
schizophrenia patients with a lower IFN-γ/IL-4 ratio (Laan et al., 2010) suggesting that the reduction 
of psychotic symptoms occurs to a greater extent among patients with relatively high levels of anti-
inflammatory cytokines. Celecoxib was also found to work with a far greater efficacy in patients 
where the concentration of soluble TNF-α receptor 1 was lower (Muller et al., 2010). 
4.3. Limitations of studies conducted so far 
Due to the small number of studies conducted to date, it is difficult to draw any strong conclusions 
regarding the efficacy of the discussed anti-inflammatory agents for clinical use in schizophrenia. 
Aspirin, estrogens and NAC are the only compounds which have been shown to improve symptom 
severity but the mechanisms of action of these compounds are very different, thus it is unclear 
whether the positive clinical effect is derived from their anti-inflammatory actions or other 
mechanisms. While studies showed improvements in PANSS scores which were the primary means 
of assessment, they did not show corresponding improvements in cognition. Estrogens may improve 
symptoms by mediating angiotensin and dopamine transmission (Sanchez et al., 2012) and aspirin 
may do so by antagonizing dysfunction of the NMDA receptor (Goff and Coyle, 2001).   
In addition, the side effect profile of using some of these drugs in conjunction with antipsychotics 
has yet to be carefully examined. It is believed that estrogens should not be taken for more than 1-2 
months, unless taken with progesterone (Sommer et al., 2014). Long-term aspirin and celecoxib use 
can be associated with a substantial risk of gastrointestinal bleeding (Sommer et al., 2014). Celecoxib 
has also been associated with an increased cardiovascular risk (Solomon et al., 2006).  
Early evidence suggests the low side effect profile of NAC may make it a preferable anti-
inflammatory agent compared to aspirin, estrogens and celecoxib. NAC’s modulation of the cystine-
glutamate antiporter makes it effective at decreasing addiction behaviour, an additional benefit for 
patients. Improvements have been reported in cocaine addicts after treatment with NAC (Schmaal 
et al., 2012). However there have been very few studies so far investigating NAC’s therapeutic 
efficacy in schizophrenia patients and those studies which have been conducted have investigated 
small patient cohorts over a short observational period. So far it is largely NSAIDs which have been 
investigated but there are a number of steroidal anti-inflammatory drugs which might be of interest, 
such as glucocorticosteroids which have been found to be effective in reducing the number of new 
psychotic episodes (Laan et al., 2009).  
5. Conclusion 
The studies discussed in this review are an attempt to highlight some of the most relevant research 
regarding the effects of antipsychotic medication on immune/inflammatory protein biomarkers 
which are frequently altered in patients.  
Extensive studies have been conducted examining peripheral alterations in patients with the aim of 
detecting relevant subgroups and enhancing the quality of therapeutic interventions. 
Immune/inflammatory abnormalities represent some of the most robustly reported findings. While 
antipsychotic medication has proven efficacious in reducing the enhanced immune/inflammatory 
changes in some patients, this is not the case in all individuals. Trials investigating efficacy of anti-
inflammatory drug add-on to existing antipsychotics have obtained encouraging results. For 
example, aspirin and celecoxib yielded the greatest benefits in patients. Other promising results 
have been achieved for estrogens and NAC. However larger clinical trials need to be conducted over 
a longer duration in order to adequately assess their efficacy and side effect profiles. 
A different approach may be needed for patients who have been infected by microbial agents such 
as T.gondii. A series of first-generation antipsychotics have been found to have anti-toxoplasma 
properties but these studies have only been conducted in vitro. Clinical use may lead to problematic 
side effects such as EPS. Further research may be warranted into new compounds such as Emodin 
which has yielded promising results in preclinical rodent models, and specific anti-parasitic agents 
such as quinolones. 
Finally, adopting a more individualized treatment approach by stratifying patients based on changes 
in biomarkers, will help to identify individuals who are more likely to respond to specific 
antipsychotic drugs and/or anti-inflammatory medications. Such an approach will also help to select 
the most effective treatments and avoid unnecessary side effects, to the benefit of both the patient 
and the healthcare service.   
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